With so many shares to choose from on the Australian share market, it can be difficult to decide which ones to buy. The good news is that brokers across the country are doing a lot of the hard work for you.
Three top ASX shares that leading brokers have named as buys this week are listed below. Here's why they are bullish on them:
Image Source: Getty Images
betr Entertainment Ltd (ASX: BBT)
According to a note out of Morgans, its analysts have retained their buy rating on this sports betting company's shares with a reduced price target of 38 cents. Morgans was pleased with the company's performance during the fourth quarter. In fact, it notes that Betr outperformed its expectations for both turnover and gross win. In addition, it was pleased to see that Betr's net win margin remained above 10% despite integrating the lower margin TopSport customer base. And with product enhancements underway, Morgans see scope for increased scale and incremental margin expansion heading into the higher-quality racing and sports finals season. The Betr share price is trading at 31 cents on Monday.
Electro Optic Systems Holdings Ltd (ASX: EOS)
A note out of Bell Potter reveals that its analysts have retained their buy rating on this defence and space company's shares with an improved price target of $3.75. Bell Potter was pleased with its second quarter update, highlighting that operating cash flow was particularly strong following the finalisation of a major contract. Looking ahead, the broker anticipates material contract awards in the second half of 2025. This includes the potential award of the HELW contract, which it thinks would be important for EOS. This is not just in terms of value but strategic significance. In light of this, the broker has boosted the multiple it uses in its EV/EBITDA valuation to 30x to reflect the significance of the HELW contract as key a driver of long-term growth. The EOS share price is fetching $2.94 at the time of writing.
ResMed Inc. (ASX: RMD)
Analysts at Citi have retained their buy rating on this sleep disorder treatment company's shares with an improved price target of $49.00. According to the note, ResMed delivered a full year result a touch ahead of expectations in FY 2025. This was driven by a combination of stronger than expected revenue and gross margins. And with management guiding to higher margins in FY 2026, the broker is feeling about its outlook over the next 12 months and suspects that it could outperform the market's expectations. The ResMed share price is trading at $42.98 on Monday.
